Leaflet ABIRATERONA STADA 500mg film-coated tablets

Product code:
W68031017
Quantity:
60
Indicated for:
prostate cancer
Route of administration:
oral
Substance:
abiraterone (antiandrogen)
ATC
L02BX03 — Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Other hormone antagonists and related agents
Abiraterone is a medication used in the treatment of metastatic castration-resistant prostate cancer. It works by inhibiting an enzyme called CYP17, which is essential for the production of androgens, hormones that stimulate the growth of prostate cancer cells.

Abiraterone is administered alongside prednisone or prednisolone to reduce side effects caused by decreased cortisol levels. Treatment with abiraterone can slow disease progression and improve patients' quality of life.

Common side effects include high blood pressure, hypokalemia (low potassium levels in the blood), and fluid retention. It is important for patients to undergo regular monitoring of liver function and blood pressure during treatment.

Abiraterone is contraindicated in pregnant or breastfeeding women and is not recommended for use in patients with severe liver impairment.

General data about ABIRATERONA STADA 500mg

Substance:
abiraterone
Date of latest medicines list:
01-06-2026
Product code:
W68031017
Concentration:
500mg
Pharmaceutical form:
film-coated tablets
Quantity:
60
Product type:
Generic medicine
Price:
8168.02 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
REMEDICA LTD - CIPRU
Holder:
STADA M&D SRL - ROMANIA
Number:
14050/2021/17
Shelf life:
2 years

Pharmaceutical forms available for abiraterone

Concentrations available for abiraterone

  • 1000mg
  • 250mg
  • 500mg

Combinations with other substances

Compensation lists for ABIRATERONA STADA 500mg STADA

NHP 3 (C2) - NHP oncology

Price
8168.02 RON
Copayment
3384.36 RON
Patient
4783.66 RON